BCRX (STOCKS)
BioCryst Pharmaceuticals Inc
$9.060000
+0.360000 (+4.14%)
Prev close: $8.700000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Charles K. Gayer
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $2,307.80M
- Employees
- 580
- P/E (TTM)
- -4.90
- P/B (TTM)
- -3.99
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
10
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.09 | $0.05 | -0.1395 | -281.82% |
|
Dec 2025 (Q4)
|
$0.01 | $0.04 | -0.0286 | -74.09% |
|
Sep 2025 (Q3)
|
$0.06 | $0.04 | +0.0241 | +67.13% |
|
Jun 2025 (Q2)
|
$0.04 | $0.01 | +0.0257 | +179.72% |
Financial Statements
| Revenues | $885.72M |
| Benefits Costs and Expenses | $1.34B |
| Cost Of Revenue | $19.88M |
| Costs And Expenses | $1.27B |
| Gross Profit | $865.83M |
| Nonoperating Income/Loss | -$72.34M |
| Operating Expenses | $1.25B |
| Selling, General, and Administrative Expenses | $360.73M |
| Research and Development | $189.18M |
| Operating Income/Loss | -$381.84M |
| Income/Loss From Continuing Operations After Tax | -$457.98M |
| Income/Loss From Continuing Operations Before Tax | -$454.18M |
| Income Tax Expense/Benefit | $3.81M |
| Net Income/Loss | -$457.98M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$457.98M |
| Net Income/Loss Available To Common Stockholders, Basic | -$457.98M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.73 |
| Diluted Earnings Per Share | -$1.77 |
| Basic Average Shares | 662,315,000 |
| Diluted Average Shares | 682,261,000 |
| Assets | $465.05M |
| Current Assets | $373.63M |
| Inventory | $5.99M |
| Other Current Assets | $367.64M |
| Noncurrent Assets | $91.43M |
| Fixed Assets | $9.37M |
| Other Non-current Assets | $82.06M |
| Liabilities | $1.02B |
| Current Liabilities | $195.39M |
| Accounts Payable | $10.96M |
| Other Current Liabilities | $184.43M |
| Noncurrent Liabilities | $823.50M |
| Equity | -$553.84M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$553.84M |
| Liabilities And Equity | $465.05M |
| Net Cash Flow From Operating Activities | $313.10M |
| Net Cash Flow From Operating Activities, Continuing | $313.10M |
| Net Cash Flow From Investing Activities | -$309.44M |
| Net Cash Flow From Investing Activities, Continuing | -$309.44M |
| Net Cash Flow From Financing Activities | $62.09M |
| Net Cash Flow From Financing Activities, Continuing | $62.09M |
| Exchange Gains/Losses | $747.00K |
| Net Cash Flow | $66.50M |
| Net Cash Flow, Continuing | $65.75M |
| Comprehensive Income/Loss | -$460.00M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$459.48M |
| Other Comprehensive Income/Loss | -$465.08M |
| Other Comprehensive Income/Loss Attributable To Parent | -$1.50M |